Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
Financials
Financial year 2025
IQVIA Cancer Research from Zaventem, company number BE0763914095, closed financial year 2025 with a result of € 38,859 after tax. For that financial year IQVIA Cancer Research recorded a gross margin of € 50,247 and equity of € -269,667. Compared with financial year 2024, the result moved from € 2,686 to € 38,859. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2026.
€ -269,667
▲ € 38,859 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 38,859
▲ € 36,173 vs 2024
Profit after tax over the fiscal year.
€ 49,130
▼ 90% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -269,767.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 14,050
▼ 95% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -112,966 | € -85,978 | € 18,152 | € 50,247 | ▲ 177% |
| Profit after taxes | € -117,893 | € -102,166 | € 2,686 | € 38,859 | ▲ € 36,173 |
| Equity | € -209,046 | € -311,212 | € -308,526 | € -269,667 | ▲ € 38,859 |
| Total debts | € 510,463 | € 552,460 | € 943,970 | € 1,341,148 | ▲ 42% |
| Cash | € 288,494 | € 236,356 | € 484,181 | € 49,130 | ▼ 90% |
| Retained profit | € -209,146 | € -311,312 | € -308,626 | € -269,767 | ▲ € 38,859 |
| Balance sheet total | € 301,417 | € 241,248 | € 635,445 | € 1,071,481 | ▲ 69% |
Key figures of IQVIA Cancer Research, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to IQVIA Cancer Research?
What happened at IQVIA Cancer Research in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 38,859 (▲ € 36,173 vs 2024). Source: NBB ↗
- Robert Kotchie became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 117,893 loss in 2022 to € 38,859 profit in 2025.
Best year ever: 2025, with € 38,859 profit.
A new publication or filing at IQVIA Cancer Research? We notify you, reason included.
Follow IQVIA Cancer ResearchDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind IQVIA Cancer Research is Robert Kotchie. The shares are held by IQVIA LTD (100%).
Directors
According to the 2025 annual accounts
Robert Kotchie
Gedelegeerd bestuurder
since 2021
Shareholders
IQVIA LTD
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Da Vincilaan 7
1930 Zaventem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →IQVIA Solutions Belgium
€ 33.1 million revenue · 2025
TAKEDA BELGIUM
€ 201.4 million revenue · 2025
IQVIA RDS & INTEGRATED SERVICES BELGIUM
€ 45.6 million revenue · 2025
IM ASSOCIATES
€ 3.1 million gross margin · 2025
Orifarm Healthcare
€ 31.3 million revenue · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0763.914.095
- VAT number
- BE 0763.914.095
- Registered office
- Da Vincilaan 7, 1930 Zaventem
- Names & denominations
- IQVIA Cancer Research
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 February 2021
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied